Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection
Authors:
- György M BuzásGBGyörgy M Buzás
- György MGMGyörgy M
- Jolán JózanJJJolán Józan
- JolánJOJolán
- 5 September 2007
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 22 (10) , 1571-1581
Abstract
Several aspects of Helicobacter pylori eradication have been meta‐analyzed; however, nitrofuran‐based therapies constitute an exception. The aim of this study was the systematic review and meta‐analysis of the effect of furazolidone‐ and nitrofurantoin‐based regimens in the eradication of infection. Studies evaluating the effects of nitrofurans on H. pylori were identified from Medline, EMBASE, the Cochrane Controlled Trials Register and congress abstracts. The studies were classified into groups based on first‐, second‐ and third‐line regimens. The pooled eradication rates and combined odd ratios of the individual studies were calculated and compared with the published meta‐analysis. The factors influencing the efficiency of the regimens were also analyzed. Side‐effects of nitrofuran‐based regimens were also analyzed. The pooled eradication rate of primary proton pump inhibitor‐based regimens containing furazolidone was 76.3% (CI 67.8–84.2). The odds ratio for furazolidone‐based regimens versus standard triple therapies was 2.34 (CI 0.76–3.92). Ranitidine bismuth citrate + furazolidone‐based triple regimens were equally efficient (83.5%, CI 74.0–93.0, P = 0.06 versus triple therapies). Schedules including a H2 antagonist + furazolidone + one other antibiotic achieved pooled eradication rates of 79.9% (CI 67.8–89.9, P = 0.04). Bismuth‐based triple therapies achieved 84.5% (CI 72.6–93.0, P = 0.002). Primary quadruple regimens containing furazolidone were superior to triple therapies (83.4%, CI 69.7–92.3, P = 0.01). Second‐line schedules containing furazolidone obtained eradication rates of 76.1% (CI 66.4–85.0, P = 0.28 versus primary regimens). Third‐line ‘rescue’ therapies were efficient in 65.5% of the cases (CI 56.3–75.5, P = 0.0001). Side‐effects of the regimens containing furazolidone were more frequent than in standard therapies (P = 0.02). The combined odds ratio of side‐effects for furazolidone‐based versus standard therapies was 0.74 (CI 0.32–1.98). The duration of treatment, but not the furazolidone dose, influenced the treatment outcome. Primary triple regimens containing furazolidone are slightly less efficient than the standard primary combinations; primary quadruple regimens were more efficient than triple therapies. Furazolidone is also efficient as a component of second‐line or rescue therapies.Keywords
This publication has 84 references indexed in Scilit:
- Naphthofuroquinone derivatives: Inhibition of receptor tyrosine kinasesBioorganic & Medicinal Chemistry Letters, 2006
- Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infectionChinese Journal of Digestive Diseases, 2005
- Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patientsAlimentary Pharmacology & Therapeutics, 2004
- H pylori antibiotic resistance: prevalence, importance, and advances in testingGut, 2004
- Basis for the Management of Drug-Resistant Helicobacter pylori InfectionDrugs, 2004
- One‐week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double‐blind studyAlimentary Pharmacology & Therapeutics, 2001
- High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 weekAlimentary Pharmacology & Therapeutics, 1999
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Liver (clinical), and paediatricsGut, 1996
- Adverse Reactions to Furazolidone and Other Drugs: A Comparative ReviewScandinavian Journal of Gastroenterology, 1989